Dye wastewater containing bisphenol A (BPA) and dyes as pollutants have not been adequately studied. Our previous study revealed that thermoplastic polyurethane (TPU) nanofiber membranes (NFMs) modified by the addition of polyethyleneimine (PEI) and polydopamine (PDA) satisfactorily adsorb dyes. Herein, we first optimized the synthesis conditions for such membranes, noting a PEI:PDA monomer ratio of 2:2 and a deposition time of 48 h to be optimal. Experiments using these membranes revealed that binary systems containing BPA and the dyes (Congo red (CR), Eosin yellow (EY), or sunset yellow (SY)) exhibit three adsorption behaviors. CR and BPA compete with each other for adsorption sites, decreasing the maximum adsorption capacity (Qmax) for CR 208.3 mg/g (in a monomeric system) to 182.4 mg/g, whereas for BPA, it decreased from 26.7 to 22.8 mg/g. The adsorption rates for CR and BPA decreased from 0.002 min−1 and 0.331 min−1 in the monomeric systems to 8.37 × 10−4 min−1 and 0.072 min−1, respectively, in the binary CR–BPA system, exhibiting antagonistic effects. When EY and BPA coexist, Qmax for EY increased from 60.0 (monomeric) to 71.9 mg/g, whereas that for BPA increased from 35.6 to 43.2 mg/g, showing a synergistic effect due to the possible bridging effect. The adsorption sites for SY and BPA are independent of each other. Thus, PDA/PEI TPU NFMs exhibit the potential for removal of dye–BPA composites, whereas binary systems containing BPA with different dyes are adsorbed differently.

Background & Aims: This RCT aimed to investigate the safety and efficacy of MF4637, a medical food comprising highly concentrated, highly purified, long chain (LC) omega-3 fatty acids, (460 mg eicosapentaenoic acid (EPA) and 380 mg docosahexaenoic acid (DHA)) in correcting the omega-3 fatty acid nutritional deficiency present in non-alcoholic fatty liver disease (NAFLD). The potential for MF4637 to reduce liver fat was evaluated in a subset of patients. Methods: 176 subjects with NAFLD were randomised to receive 3 g/d of LC-omega-3 fatty acids (n=87) or placebo (olive oil; n=89) for 24 weeks, in addition to following standard-of-care dietary guidelines for these patients. Thus, interventions were given on top of the dietary advice. The omega-3 index, omega-6:omega-3 fatty acid ratio (primary outcome) and quantitative measurements of red blood cell (RBC) EPA and DHA (secondary outcome) were determined at baseline and study completion. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) assessment of change in liver fat fraction was conducted in a subset of patients. Results: Of the 176 randomised subjects, 167 were analysed for the primary and secondary outcomes (n=81 in the MF4637 group; n=86 in the placebo group). Supplementation with MF4637 for 24 weeks significantly increased the omega-3 index and absolute values of RBC EPA and DHA, and decreased the omega-6:omega-3 fatty acid ratio in NAFLD patients compared to placebo (p<0.0001). There was a statistically significant reduction in liver fat content within both groups with no difference between them. An inverse relationship between change in absolute RBC EPA+DHA and change in liver fat, AST and ALT levels was seen suggesting that a greater increase in omega-3 content was associated with a reduction for both liver fat content and improvement in liver enzyme levels. Additionally, a significant liver fat-lowering effect of MF4637 compared to placebo was demonstrated in a subset of patients with baseline fatty liver index (FLI) score ≥ 40. There were no serious adverse events related to study interventions. Conclusions: The study results demonstrate that the medical food MF4637, was able to correct the nutritional deficiency of omega-3 in NAFLD patients above and beyond that obtained with nutritional counselling. This demonstrates that MF4637 is beneficial in raising the low omega-3 index observed in these patients. A reduction in hepatic steatosis was demonstrated with both intervention groups although no distinction between groups was seen. Further analyses demonstrate the potential to identify omega-3 sensitive patients using an easily available clinical tool for steatosis prediction.